D.A. Davidson & Co. Crispr Therapeutics Ag Transaction History

D.A. Davidson & Co.

$15.1 Billion
Q3 2025

A detailed history of D.A. Davidson & Co. transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, D.A. Davidson & Co. holds 5,379 shares of CRSP stock, worth $304,505. This represents 0.0% of its overall portfolio holdings.

Number of Shares

5,379

Holding current value

$304,505

% of portfolio

0.0%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Oct 22, 2025	BUY	$48.51 - $68.14 $260,935 - $366,525	5,379 New	5,379 $348,000
Q4 2021 Jan 31, 2022	SELL	$70.09 - $111.29 $206,204 - $327,415	-2,942 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$110.2 - $156.64 $39,231 - $55,763	356 Added 13.77%	2,942 $329,000
Q1 2021 May 07, 2021	BUY	$110.72 - $210.04 $286,321 - $543,163	2,586 New	2,586 $315,000
Q4 2018 Jan 29, 2019	SELL	$22.73 - $42.34 $179,021 - $333,469	-7,876 Closed	0 $0
Q3 2018 Nov 13, 2018	SELL	$44.35 - $65.71 $327,081 - $484,611	-7,375 Reduced 48.36%	7,876 $349,000
Q2 2018 Aug 02, 2018	SELL	$42.62 - $73.59 $42 - $73	-1 Reduced 0.01%	15,251 $896,000
Q1 2018 May 04, 2018	SELL	$23.52 - $58.17 $11,760 - $29,085	-500 Reduced 3.17%	15,252 $697,000
Q4 2017 Feb 08, 2018	BUY	$16.95 - $23.48 $266,996 - $369,856	15,752	15,752 $370,000

Others Institutions Holding CRSP

# of Institutions

542

Shares Held

68.6M

Call Options Held

3.67M

Put Options Held

2.25M

Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl

10.2M
Shares

$576 Million
4.09% of portfolio
Capital International Investors Los Angeles, CA

5.59M
Shares

$317 Million
0.05% of portfolio
T. Rowe Price Investment Management, Inc. Baltimore, MD

3.68M
Shares

$208 Million
0.11% of portfolio
State Street Corp Boston, MA

3.27M
Shares

$185 Million
0.01% of portfolio
Ubs Group Ag

2.84M
Shares

$161 Million
0.02% of portfolio

View Full List

About CRISPR Therapeutics AG

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $4.42B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

More about CRSP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D.A. Davidson & Co., based on Form 13F filings with the SEC.

News

Stay updated on D.A. Davidson & Co. with notifications on news.

Account